0001209191-18-033117.txt : 20180524 0001209191-18-033117.hdr.sgml : 20180524 20180524181453 ACCESSION NUMBER: 0001209191-18-033117 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180524 FILED AS OF DATE: 20180524 DATE AS OF CHANGE: 20180524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HEALY JAMES CENTRAL INDEX KEY: 0001245624 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 18859055 MAIL ADDRESS: STREET 1: 3000 SAND HILL ROAD, 4-250 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 2 FLOOR 3, HARCOURT CENTRE STREET 2: HARCOURT STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: BLOCK 2 FLOOR 3, HARCOURT CENTRE STREET 2: HARCOURT STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-05-24 0 0001659323 Iterum Therapeutics plc ITRM 0001245624 HEALY JAMES C/O ITERUM THERAPEUTICS LIMITED, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN L2 2 IRELAND 1 0 1 0 Series A Preferred Shares Ordinary Shares 721408 I By Sofinnova Venture Partners IX, L.P. Series B-1 Preferred Shares Ordinary Shares 275446 I By Sofinnova Venture Partners IX, L.P. Series B-2 Preferred Shares Ordinary Shares 229660 I By Sofinnova Venture Partners IX, L.P. The Series A Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series A Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. Not applicable. These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. The Reporting Person is one of the three managing members of the GP. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Fund, except to the extent of his pecuniary interest therein, if any. The Series B-1 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-1 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. The Series B-2 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-2 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. /s/ James I. Healy 2018-05-24 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY

	Know all by these presents that the undersigned hereby constitutes and appoints
each Corey N. Fishman and Judith M. Matthews of Iterum Therapeutics plc (the
"Company") and Alan Hambelton, Colleen Burns and Brian Woodard of Cooley LLP,
signing individually, the undersigned's true and lawful attorneys-in fact and
agents to:

	(1)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") Forms 3, 4 and
5 (including amendments thereto and joint filing agreements in connection
therewith) with respect to the securities of the Company in accordance with
Section 16(a) of Securities Exchange Act of 1934, as amended (the "Exchange
Act") and the rules thereunder;

	(2)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such Forms with the SEC and any stock exchange,
self-regulatory association or any other authority; and

	(3)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever which in the
good faith belief of such attorney-in-fact is requisite, necessary, or proper to
be done in the exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney in fact, or such attorney in fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted.  The undersigned acknowledges
that the foregoing attorneys-in-fact, and their substitutes, in serving in such
capacity at the request of the undersigned, are not assuming (nor is the Company
assuming) any of the undersigned's responsibilities to comply with Section 16 of
the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the attorneys-in-fact.  This Power of Attorney revokes any other
power of attorney that the undersigned has previously granted to representatives
of the Company and Cooley LLP.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated: March 8, 2018


By: /s/ James I. Healy					James I. Healy
	Signature					Printed Name